Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary - Gilde Healthcare

Menu
Menu
Home

Conatus Pharmaceuticals Acquires Pfizer’s Idun Subsidiary

29. Juli 2010

Former Idun Management team to expand efforts in liver disease and oncology
 
SAN DIEGO – Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc.  Financial terms were not disclosed.  Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and oncology.
 
Conatus Pharmaceuticals is led by Steven J. Mento, Ph.D., the former CEO of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  

” The addition of Idun to Conatus continues our important work in liver disease and expands our therapeutic reach into oncology,”

said Dr. Mento.

 ” Conatus plans to leverage its scientific and drug development expertise and resources to continue to advance potentially important therapeutic candidates in liver disease and oncology.”

Idun Pharmaceuticals was a privately-held biopharmaceutical company engaged in the discovery and development of drug candidates to control apoptosis. At the time of the acquisition by Pfizer, Idun had a Phase 2 drug candidate in liver disease (emricasan/IDN-6556), preclinical drug candidates including IDN-13389 for oncology, a development agreement with Abbott for an oncology drug candidate, and key intellectual property in the field of apoptosis.  Conatus’ SVP Corporate Development, Jennifer Giottonini Cayer added, ” We appreciate the contributions of Pfizer’s colleagues on these potentially important drug candidates.  Conatus is excited to have the opportunity to work on these programs.”  
 
Conatus Pharmaceuticals Inc. is a privately-held pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. The lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.
 
Source: Conatus Pharmaceuticals

Mehr neuigkeiten

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15. Oktober 2025

Gilde Healthcare company CatalYm announces first patient dosed in Phase 2b trial evaluating Visugromab in combination with chemoimmunotherapy as frst-line treatment in Metastatic Non-squamous NSCLC

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company’s anti-GDF-15 antibody visugromab, in combination with standard-of-care...
30. September 2025

Gilde Healthcare company CatalYm announces leadership changes to accelerate visugromab late-stage clinical development

Gilde Healthcare company CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief...
15. September 2025